coteauBeta Get App

NVS

Novartis AG
$153.93
+0.19% Oct 21 close
Healthcare Compare
-8%+1%+10%+19%+28%Oct 2025Oct 2026Apr 2026
NVSSPY
1W
+4.8%
1M
+9.2%
3M
+0.6%
6M
+4.5%
YTD
+15.0%
1Y
+20.8%

Live chart

Loading live chart…

What they do

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase.

Healthcare · Drug Manufacturers - General

For information only · Important disclosures

Grades vs sector

No sector grades for NVS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?
Insider Monkey · 16h ago
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
GlobeNewswire · 18h ago
Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors
Exec Edge · Oct 20
Just One in Ten Rheumatologists Satisfied with Current Systemic Sclerosis Treatments as Emerging Therapies Raise Expectations, According to Spherix Global Insights
GlobeNewswire · Oct 20
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
PR Newswire · Oct 20

Key stats

Market value$292.6B
P/E (last 12 months)23.3
P/E (next 12 months, estimated)15.7
52-week range$121.57 – $170.46
Revenue growth (latest quarter vs a year ago)+0.8%
Dividend yield3.09%
Analyst consensusHold (11)
Average analyst price target$154.65 (+0%)
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: 2026-10-27 · before open · EPS est 2.24
24-1025-0125-0425-0725-1026-0226-0426-070.002.42
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-07-202.152.41+12.2%
2026-04-271.651.65+0.0%
2026-02-042.002.03+1.3%
2025-10-282.312.25-2.6%
2025-07-172.372.42+2.0%
2025-04-292.172.28+5.0%
2025-01-301.761.98+12.7%
2024-10-281.932.06+6.6%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$15.0B+0.8%
2026-03-31$13.5B–
2025-12-31$13.9B–
2025-09-30$14.4B–
2025-06-30$14.8B–
Analyst actions
HSBC
2026-09-10 · up
Reduce → Hold
PT $136
Morgan Stanley
2026-03-26 · main
Overweight → Overweight
PT $170
Barclays
2026-01-06 · up
Underweight → Equal-Weight
JP Morgan
2025-12-08 · up
Neutral → Overweight
Goldman Sachs
2025-09-12 · down
Neutral → Sell
PT $118
UBS
2025-02-13 · down
Buy → Neutral

Recent dividends

2026-03-11: $4.773 · 2025-03-12: $3.994 · 2024-03-07: $3.740 · 2023-03-09: $3.469 · 2022-03-08: $3.357 · 2021-03-04: $3.378 · 2020-03-03: $3.042 · 2019-03-04: $2.567

Stats refreshed 2026-10-21 18:06:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

Beta 0.9 · Oct 21, 2026